biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Who can get to the bottom of things?

<< Previous

Bullboard Posts

Next >>

Comment by JDavenporton Dec 14, 2022 12:36pm

159 Views

Post# 35171150

RE:RE:RE:RE:Who can get to the bottom of things?

It seems to me that Dr. Deborah Rathjen has been downplaying xB3 so badly that it supports the thought that xB3 will be sold off to a third party after the deal is done. You wouldn't want those Midatech and other shareholders to gain an understanding of what xB3 is really worth. And who cares what the old Bioasis shareholders think. They don't enough to anything about anything.

As a bonus, Dr. Deborah Rathjen may be included in the sale of xB3.

Free, with a partnership coming after, a reward for her immense expertise, good behaviour.and just because.

jd

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages